Taming glioblastoma by targeting angiogenesis: 3 years later.
Eric T
ET
Wong
Steven
S
Brem
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000098:blood supply* / Q000628:therapy*; D017322:Clinical Trials, Phase II as Topic; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005909:Glioblastoma / Q000098:blood supply* / Q000628:therapy*; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000532:radiotherapy; D000077204:Temozolomide
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018906:Antineoplastic Agents, Alkylating; D000068258:Bevacizumab; D003606:Dacarbazine; D000077204:Temozolomide